Nomogram Using Prostate Health Index for Predicting Prostate Cancer in the Gray Zone:Prospective, Multicenter Study
- Author:
Jae Hoon CHUNG
1
;
Jeong Hyun KIM
;
Sang Wook LEE
;
Hongzoo PARK
;
Geehyun SONG
;
Wan SONG
;
Minyong KANG
;
Hyun Hwan SUNG
;
Hwang Gyun JEON
;
Byong Chang JEONG
;
Seong IL SEO
;
Hyun Moo LEE
;
Seong Soo JEON
Author Information
- Publication Type:Original Article
- From:The World Journal of Men's Health 2024;42(1):168-177
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To create a nomogram that can predict the probability of prostate cancer using prostate health index (PHI) and clinical parameters of patients. And the optimal cut-off value of PHI for prostate cancer was also assessed.
Materials and Methods:A prospective, multi-center study was conducted. PHI was evaluated prior to biopsy in patients requiring prostate biopsy due to high prostate-specific antigen (PSA). Among screened 1,010 patients, 626 patients with clinically suspected prostate cancer with aged 40 to 85 years, and with PSA levels ranging from 2.5 to 10 ng/mL were analyzed.
Results:Among 626 patients, 38.82% (243/626) and 22.52% (141/626) were diagnosed with prostate cancer and clinically significant prostate cancer, respectively. In the PSA 2.5 to 4 ng/mL group, the areas under the curve (AUCs) of the nomograms for overall prostate cancer and clinically significant prostate cancer were 0.796 (0.727–0.866; p<0.001), and 0.697 (0.598–0.795; p=0.001), respectively. In the PSA 4 to 10 ng/mL group, the AUCs of nomograms for overall prostate cancer and clinically significant prostate cancer were 0.812 (0.783–0.842; p<0.001), and 0.839 (0.810–0.869; p<0.001), respectively.
Conclusions:Even though external validations are necessary, a nomogram using PHI might improve the prediction of prostate cancer, reducing the need for prostate biopsies.
